The company developed the test with Boston University researchers as part of an effort to push its surface-enhanced Raman scattering tech for POC applications.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
The firm noted that it has already borrowed $350 million under the revolving credit facility. The funds may be used for general corporate and other purposes.
A new analysis of the study yielded mixed news for black women, confirming that they suffer worse outcomes, even with the same genetic test results and treatment.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
Launched to commercialize technologies from two leading glycoproteomic researchers, the startup's lead test is a mass spec-based assay for triaging pelvic masses.
